PFIZER INC
For the period ended Sep 29, 2024. Filed Nov 4, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 29, 2024 · Filed Nov 4, 2024
PFE$29.23-0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| Three Months Ended | Nine Months Ended | |||
|---|---|---|---|---|
| (MILLIONS, EXCEPT PER SHARE DATA) | September 29,2024 | October 1,2023 | September 29,2024 | October 1,2023 |
| Revenues: | ||||
| Product revenues(a) | $15,417 | $11,587 | $38,731 | $38,575 |
| Alliance revenues(a) | 1,900 | 1,645 | 6,140 | 5,672 |
| Royalty revenues(a) | 384 | 260 | 992 | 737 |
| Total revenues | 17,702 | 13,491 | 45,864 | 44,984 |
| Costs and expenses: | ||||
| Cost of sales(b), (c) | 5,263 | 9,269 | 11,942 | 17,391 |
| Selling, informational and administrative expenses(b) | 3,244 | 3,281 | 10,456 | 10,196 |
| Research and development expenses(b) | 2,598 | 2,711 | 7,787 | 7,864 |
| Acquired in-process research and development expenses | 13 | 67 | 20 | 122 |
| Amortization of intangible assets | 1,312 | 1,179 | 3,927 | 3,466 |
| Restructuring charges and certain acquisition-related costs | 313 | 155 | 1,669 | 377 |
| Other (income)/deductions––net | 243 | 181 | 2,030 | 381 |
| Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss) | 4,715 | (3,352) | 8,033 | 5,187 |
| Provision/(benefit) for taxes on income/(loss) | 234 | (964) | 393 | (320) |
| Income/(loss) from continuing operations | 4,481 | (2,388) | 7,640 | 5,507 |
| Discontinued operations––net of tax | (8) | 12 | 4 | 11 |
| Net income/(loss) before allocation to noncontrolling interests | 4,473 | (2,376) | 7,644 | 5,518 |
| Less: Net income attributable to noncontrolling interests | 8 | 6 | 23 | 30 |
| Net income/(loss) attributable to Pfizer Inc. common shareholders | $4,465 | $(2,382) | $7,621 | $5,488 |
| Earnings/(loss) per common share––basic: | ||||
| Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders | $0.79 | $(0.42) | $1.35 | $0.97 |
| Discontinued operations––net of tax | — | — | — | — |
| Net income/(loss) attributable to Pfizer Inc. common shareholders | $0.79 | $(0.42) | $1.35 | $0.97 |
| Earnings/(loss) per common share––diluted: | ||||
| Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders | $0.79 | $(0.42) | $1.34 | $0.96 |
| Discontinued operations––net of tax | — | — | — | — |
| Net income/(loss) attributable to Pfizer Inc. common shareholders | $0.78 | $(0.42) | $1.34 | $0.96 |
| Weighted-average shares––basic | 5,667 | 5,646 | 5,663 | 5,642 |
| Weighted-average shares––diluted | 5,705 | 5,646 | 5,699 | 5,714 |
(a)See Note1A.
(b)Exclusive of amortization of intangible assets.
(c)See Note 13A.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.